Literature DB >> 12702541

Bisphosphonates: new antiangiogenic molecules in cancer treatment?

B Vincenzi, D Santini, L Rocci, G Tonini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12702541     DOI： 10.1093/annonc/mdg194

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.

Authors:  Kazuho Shimura; Chihiro Shimazaki; Kyoko Taniguchi; Sonoko Akamatsu; Masashi Okamoto; Ryo Uchida; Ken-ichi Nomura; Tohru Inaba; Shigeo Horiike; Narisato Kanamura; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

2.  Bevacizumab-associated osteonecrosis of the jaw.

Authors:  S Greuter; F Schmid; T Ruhstaller; B Thuerlimann
Journal:  Ann Oncol       Date:  2008-10-31       Impact factor: 32.976

Review 3.  New therapeutic targets for cancer bone metastasis.

Authors:  Jing Y Krzeszinski; Yihong Wan
Journal:  Trends Pharmacol Sci       Date:  2015-05-09       Impact factor: 14.819

4.  Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.

Authors:  Vivek Thumbigere-Math; Bryan S Michalowicz; Pamela J Hughes; David L Basi; Michaela L Tsai; Karen K Swenson; Laura Rockwell; Rajaram Gopalakrishnan
Journal:  J Oral Maxillofac Surg       Date:  2015-10-03       Impact factor: 1.895

5.  Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature.

Authors:  Patrizia Mondello; Vincenzo Pitini; Carmela Arrigo; Stefania Mondello; Michael Mian; Giuseppe Altavilla
Journal:  Springerplus       Date:  2014-03-05

Review 6.  New Directions in the Study and Treatment of Metastatic Cancer.

Authors:  Byunghee Yoo; Bryan C Fuchs; Zdravka Medarova
Journal:  Front Oncol       Date:  2018-07-10       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.